奥赛康(002755.SZ)子公司签署ASKG712项目授权许可协议

Core Viewpoint - AskGene Pharma has entered into a licensing agreement with Visara, allowing Visara to commercialize the innovative drug project ASK712, which targets both VEGF and ANG-2 for the treatment of retinal diseases [1][2] Group 1: Licensing Agreement - The licensing agreement enables the development and commercialization of the ASK712 project in the licensed area, which is expected to positively impact the company's future performance [2] - This agreement aligns with the company's strategic focus on innovative drug development in areas such as digestion, oncology, anti-infection, and chronic diseases [2] Group 2: Drug Development - ASK712 is a first-class innovative drug developed by AskGene Pharma, currently in the IIa clinical research phase in China [1] - Clinical results from the I phase show that ASK712 has good safety and efficacy, with preclinical data indicating stronger binding activity to VEGF and ANG-2 compared to existing treatments [1]